CA-CEPTON-TECHNOLOGIES
12.1.2021 12:02:29 CET | Business Wire | Press release
Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced its path-breaking miniature lidar sensor – the Nova - priced at less than $100 for high volume automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005035/en/
The Nova is a wide angle near-range lidar sensor intended to address major gaps in proximity detection of objects with current sensor technologies. Featuring best-in-class, high resolution 3D imaging with a high field of view (FOV) of 90-120° (H) and 60-90° (V), depending on configuration, Nova sets a worldwide benchmark with its unprecedented combination of compactness, FOV coverage and affordability.
Powered by Cepton’s patented and proven Micro Motion Technology (MMT® ), the non-rotational, mirrorless, and frictionless Nova lidar can be hidden all around a vehicle to provide a complete 360° view of its immediate surroundings. With a lidar target size of 3.5 cm (W) x 3.5 cm (H) x 7.5 cm (D), and weighing less than 350 g, the ultra-small Nova is an easily embeddable lidar sensor that not only enables optimal styling choices but demonstrates the scalability of MMT® to the smallest form factors.
Nova has an angular resolution of up to 0.3°, with a maximum range of up to 30 m and is therefore ideal for automotive Advanced Driver Assistance Systems (ADAS) and autonomous vehicle (AV) applications such as blind spot detection, small object detection, automated park assist and free space estimation around the vehicle. For vehicles, a multi-lidar architecture can be facilitated, thereby creating a virtual safety zone all around while minimizing disruption to vehicle design aesthetics.
Nova is ideally suited for accurate detection of objects in proximity, such as small children, on-road objects, road edges, stationary objects and more. With this level of capability and its ultra-compact design, Nova can not only support ADAS and AV applications but also autonomous ground vehicle (AGV) and smart industrial applications.
With lidar’s increasing presence in cars and trucks, Cepton has been innovating its technology to meet the stringent requirements from OEMs and Tier 1s while striving to advance lidar designs that enable easy integration in the next generation of automobiles. Nova is the latest representation of Cepton’s state-of-the-art lidar innovation, that encompasses the goal of automotive-grade reliability, low power (<3.5 W) and high performance, along with an elegant, minimalistic design that requires only small amounts of real estate in the vehicle body.
Nova’s modular design and easily accessible components make it highly manufacturable, with very low cost at high volume. Previously, Cepton was one of the first in the industry to announce a <$1,000 volume lidar price for high performance, long range lidar (Vista-X90). Consistent with that trend, Nova is the first high field of view, near-range lidar with a <$100 price point for high automotive volumes. This fulfils Cepton’s objective to bring to market scalable, mass-market lidar solutions that enable the automotive industry to substantially accelerate safety and autonomy innovations in the next generation of vehicles.
“The Nova is an industry-first, transformational lidar that fundamentally changes the game for near-field sensing,” said Cepton CEO Dr. Jun Pei. “Currently, consumer vehicles have been limited to technologies that cannot facilitate true Level 3 or Level 4 autonomy for the mass market. Radars, cameras and ultrasonic sensors suffer from high false positives and false negatives. Rotational lidars are not embeddable, making them impractical for consumer vehicles. Near-range flash lidars either lack the wide field of view or cannot match the power and size requirements to be discretely hidden all around the vehicle. The Nova represents path-breaking lidar innovation for the automotive industry in that it achieves a level of performance that is unmatched for such a small form factor.”
Nova is targeted for high volume production starting in 2023. Due to anticipated high demand for samples, Nova will only be available to select customers in 2021 through Cepton’s Early Access Program . If you would like to be part of this program or would like more details, please contact Mitch Hourtienne, Cepton Senior Director of Business Development at mitch.hourtienne@cepton.com .
To learn more about the Nova and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming digital CES 2021, from January 11th to 14th , via our virtual booth page (CES registration required). On Jan 12th , Cepton CMO, Dr. T. R. Ramachandran will join North American Lighting (NAL) for a virtual panel discussion on “Impact of Sensors on Mobility ” at 11 a.m. (PST) and present at an online NAL-hosted webinar “Lidar, What’s the Future? ” at 2 p.m. (PST). Watch the online sessions for free to learn more about how lidar is transforming the world and how Cepton’s smart lidar solutions are ideally suited for automotive and smart infrastructure applications.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
